Over the next five years, we forecast operating profit margin to expand approximately 500 basis points, from 12.6% in 2023 to high double digits, which we think can be achieved with a combination of ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $51.48 which represents a decrease of $-1.75 or -3.29% from the prior close of $53.23. The stock opened at $53.14 and ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...

On Wednesday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $54.72 which represents a decrease of $-16.79 or -23.48% from the prior close of $71.51. The stock opened at $55.7 and ...

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.Please watch the video at Investors.com - Biotech Stocks Are ...